- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01586715
Stem Cells Treatment for Extremely Complex Fistulae (HULPCIR)
April 25, 2012 updated by: Instituto de Investigación Hospital Universitario La Paz
A Phase IIa Clinical Trial to Study the Treatment of the Extremely Complex and Conventional Treatment Resistant Perianal Fistulae With Autologous Stem Cells From Lipoaspirate
The purpose of this study is to evaluate the practicability of the autologous e-ASC (Autologous Stem Cells) for the treatment of extremely complex and treatment resistant perianal fistulae.
Study Overview
Status
Unknown
Conditions
Intervention / Treatment
Study Type
Interventional
Enrollment (Anticipated)
10
Phase
- Phase 2
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Contact
- Name: Damián García Olmo, Prof MD
- Phone Number: 0034 912071022
- Email: damian.garcia@uam.es
Study Contact Backup
- Name: Mariano A García Arranz, PhD
- Phone Number: 0034 912071022
- Email: mgarciaa.hulp@salud.madrid.org
Study Locations
-
-
-
Madrid, Spain, 28046
- Recruiting
- Hospital Universitario La Paz
-
Contact:
- Mariano A García Arranz, PhD
- Phone Number: 0034 912071022
- Email: mgarciaa.hulp@salud.madrid.org
-
Principal Investigator:
- Damián García Olmo, Prof MD
-
Sub-Investigator:
- Héctor Guadalajara Labajo, MD
-
Sub-Investigator:
- Tihomir G Hirstov, MD
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years and older (Adult, Older Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
- Signed informed consent
- Extremely Complex perianal fistulae
- Men and women over 18 years old. Good general state of health according to the findings of the clinical history and the physical examination
- Previous failure in at least one closing fistula standard treatment
Exclusion Criteria:
- Presence of severe proctitis or dominant active luminal disease requiring immediate therapy
- Patients with an abscess unless a complete toilet of the area with drainage of the collections and the absence of abscess and other collections is confirmed prior to treatment start
- Patients with a history of abuse of alcohol or other addictive substances in the 6 months prior to inclusion
- Patients with malignant tumor, except for basal cell or cutaneous squamous cell carcinoma, or patients with a prior history of malignant tumors, unless the neoplastic disease has been in remission for the previous 5 years
- Patients with cardiopulmonary disease which, in opinion of the investigator, in unstable or sufficiently serious to exclude the patient from the study.
- Patients with any type of medical or psychiatric disease which, in the opinion of the investigator, could be grounds for exclusion from study
- Patients with congenital or acquired immunodeficiencies. HIV, HBV, HCV or treponema infection, whether active or latent
- Patients who have suffering major surgery or severe trauma in the prior 6 months
- Pregnant or breastfeeding women
- Patients currently receiving, or having received within 1 month prior to enrollment into this clinical trial, any investigational drug
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Autologous Stem Cells
|
Administration will be intralesional injection of cells suspension.
They will be placed into fistula walls
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Safety of treatment of extremely complex perianal fistulae. Percentage of treated extremely complex perianal fistulae and percentage of subjects with closed fistulae
Time Frame: 16 weeks
|
Safety by control the adverse effects associated with treatment Fistula close by 3D ultrasound
|
16 weeks
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Adverse events
Time Frame: 1, 4, 12, 24 weeks
|
Control by investigation team of CRD (data collections)
|
1, 4, 12, 24 weeks
|
Quality of life assessment using the SF-12 Questionnaire
Time Frame: 1, 4, 16,24 weeks
|
Test SF-12 of quality of life
|
1, 4, 16,24 weeks
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Investigators
- Principal Investigator: Damián García Olmo, Prof MD, General Surgery Department (Hospital Universitario La Paz) and Cell Therapy laboratory
Publications and helpful links
The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.
General Publications
- Garcia-Olmo D, Garcia-Arranz M, Garcia LG, Cuellar ES, Blanco IF, Prianes LA, Montes JA, Pinto FL, Marcos DH, Garcia-Sancho L. Autologous stem cell transplantation for treatment of rectovaginal fistula in perianal Crohn's disease: a new cell-based therapy. Int J Colorectal Dis. 2003 Sep;18(5):451-4. doi: 10.1007/s00384-003-0490-3. Epub 2003 May 20.
- Garcia-Olmo D, Garcia-Arranz M, Herreros D, Pascual I, Peiro C, Rodriguez-Montes JA. A phase I clinical trial of the treatment of Crohn's fistula by adipose mesenchymal stem cell transplantation. Dis Colon Rectum. 2005 Jul;48(7):1416-23. doi: 10.1007/s10350-005-0052-6.
- Garcia-Olmo D, Herreros D, Pascual I, Pascual JA, Del-Valle E, Zorrilla J, De-La-Quintana P, Garcia-Arranz M, Pascual M. Expanded adipose-derived stem cells for the treatment of complex perianal fistula: a phase II clinical trial. Dis Colon Rectum. 2009 Jan;52(1):79-86. doi: 10.1007/DCR.0b013e3181973487.
- Aggarwal S, Pittenger MF. Human mesenchymal stem cells modulate allogeneic immune cell responses. Blood. 2005 Feb 15;105(4):1815-22. doi: 10.1182/blood-2004-04-1559. Epub 2004 Oct 19.
- Hellers G, Bergstrand O, Ewerth S, Holmstrom B. Occurrence and outcome after primary treatment of anal fistulae in Crohn's disease. Gut. 1980 Jun;21(6):525-7. doi: 10.1136/gut.21.6.525.
- García Olmo D, García-Verdugo JM, Alemany J, Gonzalez M, Gutierrez-Fuentes JA. CELL THERAPHY . Ed. Mac Graw Hill. Madrid 2007
- Bey NM. A new technique in dealing with superior rectovaginal fistulae. J. Obstrt Gynecol 1934. 41: 579-587
- Given FT Jr. Rectovaginal fistula. A review of 20 years' experience in a community hospital. Am J Obstet Gynecol. 1970 Sep 1;108(1):41-6. No abstract available.
- Daniels BT. Rectovaginal fistula: a clinical and pathological study. Doctoral dissertation. Minneapolis: University of Minnesota 1949
- LAIRD DR. Procedures used in treatment of complicated fistulas. Am J Surg. 1948 Dec;76(6):701-8. doi: 10.1016/s0002-9610(48)90211-6. No abstract available.
- Hoexter B, Labow SB, Moseson MD. Transanal rectovaginal fistula repair. Dis Colon Rectum. 1985 Aug;28(8):572-5. doi: 10.1007/BF02554145.
- Fry RD, Shemesh EI, Kodner IJ, Timmcke A. Techniques and results in the management of anal and perianal Crohn's disease. Surg Gynecol Obstet. 1989 Jan;168(1):42-8.
- Radcliffe AG, Ritchie JK, Hawley PR, Lennard-Jones JE, Northover JM. Anovaginal and rectovaginal fistulas in Crohn's disease. Dis Colon Rectum. 1988 Feb;31(2):94-9. doi: 10.1007/BF02562636.
- Tuxen PA, Castro AF. Rectovaginal fistula in Crohn's disease. Dis Colon Rectum. 1979 Jan-Feb;22(1):58-62. doi: 10.1007/BF02586761. No abstract available.
- Bandy LC, Addison A, Parker RT. Surgical management of rectovaginal fistulas in Crohn's disease. Am J Obstet Gynecol. 1983 Oct 15;147(4):359-63. doi: 10.1016/s0002-9378(16)32225-6.
- Bauer JJ, Sher ME, Jaffin H, Present D, Gelerent I. Transvaginal approach for repair of rectovaginal fistulae complicating Crohn's disease. Ann Surg. 1991 Feb;213(2):151-8. doi: 10.1097/00000658-199102000-00010.
- Tsang CB, Madoff RD, Wong WD, Rothenberger DA, Finne CO, Singer D, Lowry AC. Anal sphincter integrity and function influences outcome in rectovaginal fistula repair. Dis Colon Rectum. 1998 Sep;41(9):1141-6. doi: 10.1007/BF02239436.
- Andreani SM, Dang HH, Grondona P, Khan AZ, Edwards DP. Rectovaginal fistula in Crohn's disease. Dis Colon Rectum. 2007 Dec;50(12):2215-22. doi: 10.1007/s10350-007-9057-7. Epub 2007 Sep 11.
- Puissant B, Barreau C, Bourin P, Clavel C, Corre J, Bousquet C, Taureau C, Cousin B, Abbal M, Laharrague P, Penicaud L, Casteilla L, Blancher A. Immunomodulatory effect of human adipose tissue-derived adult stem cells: comparison with bone marrow mesenchymal stem cells. Br J Haematol. 2005 Apr;129(1):118-29. doi: 10.1111/j.1365-2141.2005.05409.x.
- Tse WT, Pendleton JD, Beyer WM, Egalka MC, Guinan EC. Suppression of allogeneic T-cell proliferation by human marrow stromal cells: implications in transplantation. Transplantation. 2003 Feb 15;75(3):389-97. doi: 10.1097/01.TP.0000045055.63901.A9.
- Chamberlain G, Fox J, Ashton B, Middleton J. Concise review: mesenchymal stem cells: their phenotype, differentiation capacity, immunological features, and potential for homing. Stem Cells. 2007 Nov;25(11):2739-49. doi: 10.1634/stemcells.2007-0197. Epub 2007 Jul 26.
- Le Blanc K, Ringden O. Immunobiology of human mesenchymal stem cells and future use in hematopoietic stem cell transplantation. Biol Blood Marrow Transplant. 2005 May;11(5):321-34. doi: 10.1016/j.bbmt.2005.01.005.
- Maccario R, Podesta M, Moretta A, Cometa A, Comoli P, Montagna D, Daudt L, Ibatici A, Piaggio G, Pozzi S, Frassoni F, Locatelli F. Interaction of human mesenchymal stem cells with cells involved in alloantigen-specific immune response favors the differentiation of CD4+ T-cell subsets expressing a regulatory/suppressive phenotype. Haematologica. 2005 Apr;90(4):516-25.
- Barrett AJ, Rezvani K, Solomon S, Dickinson AM, Wang XN, Stark G, Cullup H, Jarvis M, Middleton PG, Chao N. New developments in allotransplant immunology. Hematology Am Soc Hematol Educ Program. 2003:350-71. doi: 10.1182/asheducation-2003.1.350.
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
March 1, 2012
Primary Completion (Anticipated)
May 1, 2013
Study Completion (Anticipated)
December 1, 2013
Study Registration Dates
First Submitted
April 23, 2012
First Submitted That Met QC Criteria
April 25, 2012
First Posted (Estimate)
April 27, 2012
Study Record Updates
Last Update Posted (Estimate)
April 27, 2012
Last Update Submitted That Met QC Criteria
April 25, 2012
Last Verified
April 1, 2012
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- HULPCIR-2010-01
- 2010-024329-19 (EudraCT Number)
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Extremely Complex Perianal Fistulae
-
Anterogen Co., Ltd.TerminatedComplex Perianal FistulaKorea, Republic of
-
Anterogen Co., Ltd.TerminatedPerianal Fistula | Primary; ComplexKorea, Republic of
-
Jiangsu Topcel-KH Pharmaceutical Co., Ltd.Xiangya Hospital of Central South UniversityNot yet recruiting
-
Tigenix S.A.U.Completed
-
TakedaTakeda Development Center Americas, Inc.RecruitingCrohn's Disease | Complex Perianal FistulaIsrael, Japan, Netherlands, Spain, Poland
-
Tigenix S.A.U.TerminatedCrohn Disease | Complex Perianal FistulaSpain, Netherlands, Austria
-
TakedaTakeda Development Center Americas, Inc.Active, not recruitingCrohn's Disease | Complex Perianal FistulaIsrael, Spain, Germany, Austria, France, Czechia
-
TakedaActive, not recruitingCrohn's Disease | Complex Perianal FistulaUnited States, Spain, France, Belgium, Israel, Czechia, Italy, Poland, Hungary
-
TakedaActive, not recruitingCrohn Disease | Complex Perianal FistulaFrance, Germany, Netherlands, Spain
-
TakedaCompletedComplex Perianal Fistulas in Adult Participants With Crohn's DiseaseJapan
Clinical Trials on Adipose-derived stem cells without expanded
-
Instituto de Investigación Hospital Universitario...UnknownRecto-vaginal FistulaSpain
-
Instituto de Investigación Hospital Universitario...UnknownEnterocutaneous FistulaSpain
-
Instituto de Investigación Hospital Universitario...UnknownStem Cells Tratment for the Local Feminine Stress Urinary Incontinence Treatment (HULPURO) (HULPURO)Urinary IncontinenceSpain
-
Instituto de Investigación Hospital Universitario...Unknown
-
University Hospital, ToulouseCentre National de la Recherche Scientifique, France; French Blood Establishment and other collaboratorsCompletedCardiovascular Diseases | Peripheral Vascular DiseasesFrance
-
Andalusian Network for Design and Translation of...Completed
-
Fundacion para la Investigacion Biomedica del Hospital...CompletedCrohn Disease | Rectovaginal FistulaSpain
-
Martha Haahr M.DOdense University HospitalUnknownDelayed Graft FunctionDenmark
-
Bioheart, Inc.WithdrawnChronic Obstructive Pulmonary DiseaseUnited States
-
Bioheart, Inc.WithdrawnDry Macular DegenerationUnited States